SeHA and SeFAc were able to manage the typical hypertensive component of MetS, attributed to the presence of rosmarinic and caffeic acids, isosa-kuranetin-5-O-rutinoside, and neoeriocitrin that inhibit angiotensin-converting enzyme (ACE) [16,17]. Here, ACE is linked to metabolic syndrome.